Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-02-27 14:23:10
The biotech industry is constantly evolving with new advancements in science and technology. Keeping up with the latest developments in this field is crucial for staying informed and making informed decisions. One way to stay on top of the science and politics driving biotech today is by signing up to receive a biotech newsletter in your inbox. This newsletter provides valuable insights into the latest trends and innovations shaping the future of health and life sciences.
The 2024 STATUS List has recently been unveiled, showcasing the 50 most influential people who are shaping the future of health and life sciences. These individuals have made significant contributions across various sectors, including biotech, medicine, health care, policy, and health tech. It is essential to recognize and celebrate their achievements as they continue to drive innovation and progress in the industry.
In recent news, Viking Therapeutics reported positive results from a mid-stage study of its obesity drug VK2735. The study showed an average weight loss of 13% after 13 weeks, with mild to moderate gastrointestinal side effects. The company’s stock price doubled in pre-market trading, highlighting the potential impact of this new drug on the market.
GSK also made headlines with its experimental oral antibiotic, gepotidacin, which successfully cleared gonorrhea in patients. The drug performed as well as the standard treatment for this antibiotic-resistant infection, offering hope for patients and healthcare providers facing this growing challenge.
On the legislative front, Congress recently dropped PBM reform from an upcoming federal funding bill. While there is bipartisan interest in addressing the issues surrounding pharmacy benefit managers, negotiations on this topic may continue in future legislation. The decision to postpone PBM reform is a surprising development, considering the significant efforts made by both the House and Senate to address this issue.
The FDA’s approval of the abortion drug mifepristone has sparked a debate, with anti-abortion advocates raising concerns about its safety. However, the rigorous approval process and safeguards put in place around mifepristone were designed to address political controversies rather than physical risks. The drug has undergone extensive studies and scrutiny to ensure its safety and efficacy for patients.
Overall, the biotech industry continues to drive innovation and progress in health and life sciences. By staying informed and following the latest developments in this field, individuals can contribute to the advancement of science and technology for the benefit of society. Consider signing up for a biotech newsletter to receive regular updates and insights on the science and politics shaping the biotech industry today.
